Foresite recruits Principia vet Martin Babler — and his old team — to occupy the C-suite of a startup
23 Sep 2021
Almost a year to the day after Sanofi closed on its $3.7 billion Principia buyout, handing CEO Martin Babler $81 million for his chunk of equity, the biotech exec is ending his sabbatical and getting back to the helm of a startup. And he’s bringing the old Principia team along with him for the R&D scrimmage ahead.
Babler is taking over the top post at Esker Therapeutics from June Lee, who helped found the upstart, which Foresite hatched out of its labs and endowed with a $70 million launch round. The immunology specialist broke out of stealth mode back in May with a tiny staff and a Phase I plan for a TYK2 drug — initially for psoriasis — part of its plan to address genetically defined patient groups in a field dominated by blockbusters and blockbuster wannabes.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.